Cardiac Troponin
The most specific blood test for myocardial injury — the cornerstone of heart attack diagnosis
When heart muscle cells die, troponin leaks into the bloodstream within hours. A rising and falling pattern of high-sensitivity troponin is how every emergency department in the world diagnoses heart attacks — and rules them out within 1–2 hours.
Cardiac troponins (cTnI and cTnT) regulate the calcium-dependent interaction of actin and myosin in heart muscle. They are exquisitely cardiac-specific — skeletal muscle troponins are genetically distinct and not detected by cardiac assays. Any process disrupting cardiomyocyte membrane integrity releases troponin — making it a marker of myocardial injury from any cause, not just ischaemia.
Reference Ranges
How clinicians interpret Troponin I / Troponin T results — from optimal to concerning.
⚠ Reference ranges vary by laboratory and assay. Always interpret your result in context of your laboratory's own reference intervals and your clinical presentation.
What raises Troponin I / Troponin T
Coronary artery occlusion causes ischaemic cell death — rising troponin + ECG changes = immediate PCI pathway.
Chronically elevated (stable) troponin in HF reflects ongoing cardiomyocyte stress — correlates with prognosis.
Massive PE causes right heart strain. Elevated troponin in PE predicts in-hospital mortality.
Viral, autoimmune, or drug-induced — cardiomyocyte necrosis with normal coronary arteries on angiography.
Catecholamine-driven apical ballooning — troponin elevated but lower than typical STEMI.
Reduced clearance and ongoing cardiomyocyte stress — elevated troponin must always be compared to baseline.
What lowers Troponin I / Troponin T
After primary PCI, troponin may peak higher (reperfusion washout) then falls within 24–48h.
Troponin normalises over 1–3 weeks as cardiac inflammation resolves.
Conditions this biomarker signals
When Troponin I / Troponin T is outside normal range, these are the most clinically significant possibilities.
Troponin + ST elevation + symptoms = immediate PCI pathway. Door-to-balloon target: < 90 minutes.
Elevated troponin + symptoms without ST elevation. Risk-stratified management (TIMI/GRACE score).
Troponin + BNP both elevated = high-risk PE — consider thrombolysis.
Young patient + viral prodrome + chest pain + elevated troponin + clear coronaries = myocarditis.
Which tests measure this biomarker
Troponin I / Troponin T may be included in or ordered alongside these panels.
ESC 0h/1h algorithm enables rapid rule-in/rule-out. Pattern (rise or fall ≥ 20%) matters as much as absolute level.
Older assay, less sensitive — used in some centres. Longer observation window required.
The troponin complex: from cardiac regulation to diagnostic tool
The troponin complex (TnI + TnT + TnC) is bound to the thin filament of cardiac myofibrils. TnC binds calcium; TnI inhibits actin-myosin binding at rest; TnT anchors the complex. During myocyte death, cytoplasmic free troponin is released first (causing the early rise at 3–6h), then structural troponin from degrading myofibrils is released more slowly (sustaining elevation for 7–10 days). This biphasic release pattern means troponin remains detectable for up to 10 days after MI — allowing late presentation diagnosis.
hs-Troponin enables 1-hour rule-out
The ESC 0h/1h algorithm uses high-sensitivity troponin at 0h and 1h. If both are very low (< 5 ng/L hs-TnT) and symptoms are non-cardiac, 99.5% of MIs are excluded. This algorithm has transformed chest pain protocols globally — enabling safe ED discharge within 1–2 hours instead of 6–12h observation.
Sex-specific cut-offs diagnose 20% more MIs in women
The 99th percentile for hs-TnI is higher in men than women (34 vs 16 ng/L). Using sex-specific thresholds increases NSTEMI diagnosis in women by ~20% — previously missed because female troponins are lower at baseline, so the same rise was falling below the universal (male-dominated) cut-off.
cTnI and cTnT are different proteins on different assays
Troponin I and T are different cardiac proteins — each lab uses one or the other. cTnT is manufactured exclusively by Roche (patented); cTnI assays are made by multiple manufacturers with varying cut-offs. Results are not interchangeable between assays — always interpret against the same assay's specific 99th percentile.
Clinical use — when and why this is ordered
How clinicians use Troponin I / Troponin T in practice — the real-world scenarios where it changes decisions.
Chest pain triage
Serial hs-troponin at 0h and 1–2h enables safe rapid discharge of non-cardiac chest pain within 2–3 hours using validated algorithms.
Heart failure prognosis
Even mild chronic troponin elevation in HF predicts hospitalisation and mortality — used alongside BNP for risk stratification.
PE risk stratification
Troponin + BNP together identify submassive/high-risk PE where catheter-directed therapy should be considered.
Chemotherapy cardiotoxicity
Serial troponin detects cardiomyocyte injury during anthracycline/trastuzumab therapy — before ejection fraction decline occurs.